LangjieRui Biotech Completes RMB 50 Million Angel Financing to Advance Pipeline Product Development

Recently, VCBeat learned that Langjierui (Suzhou) Biotechnology Co., Ltd. (“Langjierui”) announced the completion of a RMB 50 million angel financing round, led by Shenzhen Qianhai Wanrong Hongtu Investment Fund (Limited Partnership) (“Wanrong Hongtu”), with participation from Junshang Capital and the Park Science and Technology Innovation Fund. The proceeds from this round will be primarily used to advance the product development of Langjierui’s two Phase I clinical pipeline candidates.

Longjierui was established on December 28, 2020, and is dedicated to the development of novel metabolic checkpoint modulators. Its product pipeline focuses on the research and development of original innovative drugs for major chronic diseases closely associated with metabolic checkpoints, including cancer, autoimmune diseases, neurodegenerative diseases, polyarteritis and phlebitis, and aging.

Langjierui remains steadfast in its vision and mission, grounded in the principle of promoting human health through medicine, guided by clinical needs, driven by innovation, and focused on metabolic checkpoint modulators as its core therapeutic axis. The company is committed to establishing itself as a leading enterprise in the biopharmaceutical industry, consistently pioneering innovation and staying at the forefront of the field.

Shenzhen Qianhai Wanrong Hongtu Investment Fund“Longjie Rui is a flagship leading project in the Suzhou Industrial Park, having received significant attention and support from the government. Its founding team features comprehensive disciplinary expertise and has developed strong synergy through decades of collaboration. The company’s core products target major diseases closely associated with metabolic checkpoints, involving targets such as ACAT1, SIRT2, and OXCT1. We believe that the Longjie Rui team will continue to drive the development of its product pipeline, delivering revolutionary innovative therapies to patients worldwide.”

Chen Lian, Deputy General Manager of Lingjun Venture Capital, the Fund Manager of Suzhou Industrial Park Science and Technology Innovation FundMr. [Name] stated, “Biopharmaceuticals is a key industry prioritized for support and development in the Suzhou Industrial Park, and research on metabolic checkpoints represents a highly promising frontier. LongJieRui has assembled top-tier domestic talent in drug R&D and has dedicated many years to in-depth research on the molecular mechanisms underlying metabolic checkpoints and the onset and progression of chronic diseases. We are confident that LongJieRui will establish China’s first innovative drug R&D platform focused on metabolic checkpoint modulators, leverage this platform to develop multiple ‘first-in-class’ products, and emerge as a leading enterprise in drug R&D within the Park.”

Shenzhen Qianhai Wanrong Hongtu Investment Fund (Limited Partnership) (“Wanrong Hongtu”) and the offshore West Fountain Global Fund LP (“West Fountain”) constitute a parallel fund structure. This RMB-USD parallel fund, established and managed by Shenzhen Capital Group Co., Ltd. (SCGC), is collectively referred to as the “Wanrong Hongtu China-US Fund.” With a total size equivalent to approximately RMB 4 billion, the fund primarily engages in venture capital investments in high-tech enterprises both domestically and internationally, as well as cross-border mergers and acquisitions. Wanrong Hongtu’s investment philosophy is to “invest in the smartest companies to solve the most challenging problems,” while upholding SCGC’s vision of “discovering and empowering great enterprises.”

Junshang Capital was established in April 2018 as a Suzhou-based private equity firm. Rooted in the Yangtze River Delta region, the company has deeply cultivated industries such as biopharmaceuticals and intelligent equipment. Since its inception, Junshang Capital has adhered to the fundamental principle of safeguarding investors’ interests, strictly maintained compliance and risk control standards, and persisted in value-oriented investment. The company continuously strengthens its team building and is committed to creating value for clients and providing services to enterprises.

The Suzhou Industrial Park Science and Technology Innovation Fund was established under the leadership of the Science and Technology Innovation Committee and the Enterprise Service Center of Suzhou Industrial Park. It primarily invests in high-quality technology projects that align with the development directions of strategic emerging industries—such as biopharmaceuticals, nanotechnology applications, and artificial intelligence—and possess technological advancement, industrial driving capacity, and broad market prospects. With a total size of RMB 1.5 billion for its first phase, the fund will focus on key areas within these strategic emerging industries, adopting a combination of direct investment and grant-linked investment to support enterprises in scaling up, optimizing operations, and strengthening competitiveness, while also attracting more high-quality projects to settle and develop in the region.